RxDoctor Payments Data

Eustace Fernandes, MD

Pulmonary Disease · Fort Wayne, INNPI 1821040791

Payments from drug & device makers

$7,379in general payments, 2019–2025

Across 151 payments — averaging $48.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • AstraZeneca$487
  • Boehringer Ingelheim$285
  • GSK$241
  • Sanofi$204
  • Regeneron Healthcare Solutions, Inc.$160
  • plus $904 from 17 others

What the payments were for

  • Travel & lodging$1,69523%
  • Food & beverage$2,37532%
  • Education$3,08642%
  • Gifts$2233%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,379 in reported general payments places this provider in the 70th percentile of 258 pulmonary disease providers in Indiana.

See all pulmonary disease providers in Indiana

Medicare billing

Part B allowed, 2024
$111,475
Medicare patients
499
Services billed
1,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrikaftaElexacaftor/Tezacaftor/Ivacaft60$1,580,347
OfevNintedanib Esylate56$688,905
GlassiaAlpha-1-Proteinase Inhibitor19$395,336
Trelegy ElliptaFluticasone/Umeclidin/Vilanter345$337,415
Tyvaso DpiTreprostinil11$247,849
Dupixent PenDupilumab60$242,991
CreonLipase/Protease/Amylase33$127,091
Breztri AerosphereBudesonide/Glycopyr/Formoterol121$108,297
Breo ElliptaFluticasone/Vilanterol102$58,697
Ambrisentan24$49,972
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$26,934
Spiriva HandihalerTiotropium Bromide22$11,949
DuleraMometasone/Formoterol17$8,423
Fluticasone-SalmeterolFluticasone Propion/Salmeterol45$4,825
Albuterol Sulfate HfaAlbuterol Sulfate141$3,979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$285$688,90556 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$241$423,046480 claims
AbbVieCreon$58$127,09133 claims
AstraZenecaBreztri Aerosphere$487$108,297121 claims
MerckDulera$64$8,42317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 258 pulmonary disease providers in Indiana.

Other pulmonary disease in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →